Cargando…

Lipid-chitosan hybrid nanoparticles for controlled delivery of cisplatin

Lipid-polymer hybrid nanoparticles (LPHNP) are delivery systems for controlled drug delivery at tumor sites. The superior biocompatible properties of lipids and structural advantages of polymers can be obtained using this system for controlled drug delivery. In this study, cisplatin-loaded lipid-chi...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Muhammad Muzamil, Madni, Asadullah, Torchilin, Vladimir, Filipczak, Nina, Pan, Jiayi, Tahir, Nayab, Shah, Hassan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6711028/
https://www.ncbi.nlm.nih.gov/pubmed/31357896
http://dx.doi.org/10.1080/10717544.2019.1642420
_version_ 1783446453601959936
author Khan, Muhammad Muzamil
Madni, Asadullah
Torchilin, Vladimir
Filipczak, Nina
Pan, Jiayi
Tahir, Nayab
Shah, Hassan
author_facet Khan, Muhammad Muzamil
Madni, Asadullah
Torchilin, Vladimir
Filipczak, Nina
Pan, Jiayi
Tahir, Nayab
Shah, Hassan
author_sort Khan, Muhammad Muzamil
collection PubMed
description Lipid-polymer hybrid nanoparticles (LPHNP) are delivery systems for controlled drug delivery at tumor sites. The superior biocompatible properties of lipids and structural advantages of polymers can be obtained using this system for controlled drug delivery. In this study, cisplatin-loaded lipid-chitosan hybrid nanoparticles were formulated by the single step ionic gelation method based on ionic interaction of positively charged chitosan and negatively charged lipid. Formulations with various chitosan to lipid ratios were investigated to obtain the optimal particle size, encapsulation efficiency, and controlled release pattern. Transmission electron microscope and dynamic light scattering analysis demonstrated a size range of 181–245 nm and a zeta potential range of 20–30 mV. The stability of the formulation was demonstrated by thermal studies. Cytotoxicity and cellular interaction of cisplatin-loaded LPHNP were investigated using in vitro cell-based assays using the A2780 ovarian carcinoma cell line. The pharmacokinetics study in rabbits supported a controlled delivery of cisplatin with enhanced mean residence time and half-life. These studies suggest that cisplatin loaded LPHNP have promise as a platform for controlled delivery of cisplatin in cancer therapy.
format Online
Article
Text
id pubmed-6711028
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-67110282019-09-05 Lipid-chitosan hybrid nanoparticles for controlled delivery of cisplatin Khan, Muhammad Muzamil Madni, Asadullah Torchilin, Vladimir Filipczak, Nina Pan, Jiayi Tahir, Nayab Shah, Hassan Drug Deliv Research Article Lipid-polymer hybrid nanoparticles (LPHNP) are delivery systems for controlled drug delivery at tumor sites. The superior biocompatible properties of lipids and structural advantages of polymers can be obtained using this system for controlled drug delivery. In this study, cisplatin-loaded lipid-chitosan hybrid nanoparticles were formulated by the single step ionic gelation method based on ionic interaction of positively charged chitosan and negatively charged lipid. Formulations with various chitosan to lipid ratios were investigated to obtain the optimal particle size, encapsulation efficiency, and controlled release pattern. Transmission electron microscope and dynamic light scattering analysis demonstrated a size range of 181–245 nm and a zeta potential range of 20–30 mV. The stability of the formulation was demonstrated by thermal studies. Cytotoxicity and cellular interaction of cisplatin-loaded LPHNP were investigated using in vitro cell-based assays using the A2780 ovarian carcinoma cell line. The pharmacokinetics study in rabbits supported a controlled delivery of cisplatin with enhanced mean residence time and half-life. These studies suggest that cisplatin loaded LPHNP have promise as a platform for controlled delivery of cisplatin in cancer therapy. Taylor & Francis 2019-07-29 /pmc/articles/PMC6711028/ /pubmed/31357896 http://dx.doi.org/10.1080/10717544.2019.1642420 Text en © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Khan, Muhammad Muzamil
Madni, Asadullah
Torchilin, Vladimir
Filipczak, Nina
Pan, Jiayi
Tahir, Nayab
Shah, Hassan
Lipid-chitosan hybrid nanoparticles for controlled delivery of cisplatin
title Lipid-chitosan hybrid nanoparticles for controlled delivery of cisplatin
title_full Lipid-chitosan hybrid nanoparticles for controlled delivery of cisplatin
title_fullStr Lipid-chitosan hybrid nanoparticles for controlled delivery of cisplatin
title_full_unstemmed Lipid-chitosan hybrid nanoparticles for controlled delivery of cisplatin
title_short Lipid-chitosan hybrid nanoparticles for controlled delivery of cisplatin
title_sort lipid-chitosan hybrid nanoparticles for controlled delivery of cisplatin
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6711028/
https://www.ncbi.nlm.nih.gov/pubmed/31357896
http://dx.doi.org/10.1080/10717544.2019.1642420
work_keys_str_mv AT khanmuhammadmuzamil lipidchitosanhybridnanoparticlesforcontrolleddeliveryofcisplatin
AT madniasadullah lipidchitosanhybridnanoparticlesforcontrolleddeliveryofcisplatin
AT torchilinvladimir lipidchitosanhybridnanoparticlesforcontrolleddeliveryofcisplatin
AT filipczaknina lipidchitosanhybridnanoparticlesforcontrolleddeliveryofcisplatin
AT panjiayi lipidchitosanhybridnanoparticlesforcontrolleddeliveryofcisplatin
AT tahirnayab lipidchitosanhybridnanoparticlesforcontrolleddeliveryofcisplatin
AT shahhassan lipidchitosanhybridnanoparticlesforcontrolleddeliveryofcisplatin